OnCo
ideasIdea

Recover legacy radium-226 sources worldwide as the feedstock for actinium-225

Thousands of old radium sources sit in hospital and industrial storage. They are exactly the raw material needed to make actinium-225, the scarcest cancer isotope.

Actinium-225 supply from thorium-229 generators (the legacy US and Russian stockpiles) is limited to tens of curies a year, far short of projected demand for alpha radioligand therapy. Accelerator routes (radium-226 irradiated in cyclotrons, linacs or via spallation at TRIUMF) scale with radium feedstock. Radium-226 exists in large quantities in disused brachytherapy sources, industrial gauges and uranium mill tailings, currently classed as waste and expensive to store. The proposal is a coordinated recovery, purification and target-fabrication programme run with the IAEA and national nuclear agencies, offering source holders free disposal in exchange for the material.

Hypothesis
Recovered radium-226 sufficient to supply multiple accelerator producers can be secured within five years at a cost per curie of actinium-225 below the thorium-generator route, lifting global actinium-225 output by an order of magnitude.
Rationale
Radium disposal is already a cost that source holders would pay to avoid, and purification chemistry is established. The binding constraint on the accelerator route is licensed feedstock, not physics.
What would test it
Inventory recoverable radium-226 in ten countries, run a pilot recovery of 50 grams with one accelerator producer, and price the resulting actinium-225 against current generator supply.
Maturity
early clinical
Who has to act
policy
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

7top